Regulatory
The latest in regulatory for medical-aesthetics practice owners.
Regulatory
Mexico approves Restylane Shaype for jawline first
Galderma's firmer HA gel now has a Mexican approval for jawline definition, the first anywhere in the world for that area.
Regulatory
Trifluent recalls Tridacaine III lidocaine patch
The FDA recall list names Trifluent Pharma's Tridacaine III Lidocaine Patch 5%, but the listing excerpt gives almost no detail on why.
Regulatory
FDA clears Shenzhen Bway red/NIR LED face mask
A China-based applicant won a 510(k) for eight LED face mask models sold as over-the-counter wrinkle reduction devices.
Regulatory
Judge bars Medicare price for Botox over plasma rule
A D.C. federal judge ruled Botox should have been excluded from Medicare's third negotiation round, and HHS has not said whether it will appeal.
Regulatory
FDA clears AMIRO LED wrinkle mask under 510(k)
Shenzhen Accompany Technology's over-the-counter light mask was found substantially equivalent to a predicate, and the FDA listing says little more.
Regulatory
Inibio's Inibo wins China approval, third Korean toxin
China's NMPA has approved Inibio's type-A botulinum toxin, with commercial launch targeted for Q1 2027.
Regulatory
Galderma's Relfydess Approved in China for Frown Lines
China's NMPA has approved Relfydess, a ready-to-use liquid neuromodulator, for moderate-to-severe glabellar lines, marking Galderma's entry into one of the world's largest aesthetics markets.
Regulatory
Sisram's Profhilo clears China regulatory hurdle
The Hong Kong-listed company's hyaluronate injectable has won NMPA acceptance for its facial indication, setting up a China launch.
Regulatory
Allergan gets Health Canada nod for Boey, a fast-acting short-duration toxin
Boey (trenibotulinumtoxinE) is authorized in Canada for glabellar lines and works in hours instead of days, with effects lasting two to three weeks.
Regulatory
Indiana Tightens Medical Spa Regulations Under Public Law 136
New state law raises licensing and supervision requirements, affecting independent medspa operations and staffing models.
Regulatory
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
Patent litigation over syringe technology could affect filler supply and pricing dynamics.
Regulatory
Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement
CMS includes Botox among 15 drugs eligible for Medicare price negotiation in 2026, signaling payer focus on high-volume, high-cost injectables.
Regulatory
Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know
The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.
Regulatory
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.